Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans
The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...
Vincerx Pharma files $100M mixed securities shelf
EST Vincerx Pharma (VINC) files $100M mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover ...
Vincerx Pharma and Oqory reveal merger and cancer drug data
SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...
ETF Daily News5d
Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split
Vincerx Pharma, Inc., a biopharmaceutical company focused on developing innovative therapeutics for cancer patients, announced a significant corporate action regarding its common stock.
Taiwan News6d
Vincerx Pharma, Inc. Announces Reverse Stock Split
SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through ...
Investing3d
Vincerx Pharma Inc (VINC)
Get an in-depth profile of Vincerx Pharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information. Vincerx ...
VINC stock touches 52-week low at $1.62 amid market challenges
In a turbulent market environment, VINC stock has reached its 52-week low, trading at $1.62, with technical indicators from InvestingPro showing the stock in oversold territory. This price level ...